CSF beta-amyloid, cognition, and APOE genotype in alzheimer's disease

Neurology

Volumn 52, Issue 3, 1999, Pages 547-551

  Samuels, Steven C ^a,e   Silverman, J M ^a   Marin, D B ^a   Peskind, E R ^b,c   Younki, S G ^d   Greenberg, D A ^a   Schnur, E ^a   Santoro, J ^a   Davis, K L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d MAYO CLINIC   (United States)

^e MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 0032977604     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.3.547     Document Type: Article

References (35)

1. Haass C, Selkoe DJ. Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. Cell 1993;75:1039-104 2.
2. Kang J, Lemaire onset, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-736.
3. Robakis NK, Pangalos MN. Involvement of amyloid as a central step in the development of Alzheimer's disease. Neurobiol Aging 1994;15(suppl 2):S127-S129.
4. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990;250:279-282.
5. Cummings BJ, Cotman CW. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet 1995;346:1524-1528.
6. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992;359:325-327.
7. Nakamura T, Shoji M, Harigaya Y, et al. Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol 1994;36:903-911.
8. Southwick PC, Yamagata SK, Echols CL Jr, et al. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J Neurochem 1996;66:259-265.
9. van Gool WA, Kuiper MA, Walstra GJ, et al. Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;37:277-279.
10. Nitsch RM, Rebeck GW, Deng M, et al. Cerebrospinal fluid levels of amyloid beta-protein in Alzheimer's disease: inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 1995;37:512-518.
11. Pirttila T, Kim KS, Mehta PD, et al. Soluble amyloid beta-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. J Neurol Sci 1994;127:90-95.
12. Tamaoka A, Sawamura N, Fukushima T, et al. Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease. J Neurol Sci 1997;148:41-45.
13. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
14. Lannfelt L, Basun H, Vigo-Pelfrey C, et al. Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation. Neurosci Lett 1995;199:203-206.
15. Samuels SC, Davis KL. Dementia and delirium. In: Enna SJ, Coyle JT. Pharmacological management of neurological and psychiatric disorders. New York: McGraw-Hill, 1998:267-316.
16. Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein ε4 allele in patients with Alzheimer's disease. Ann Neurol 1993; 34:752-754.
17. Rebeck GW, Reiter JS, Strickland DK, et al. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993;11:575-580.
18. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
19. Myers RH, Schaefer EJ, Wilson PWF, et al. Apolipoprotein E ε4 association with dementia in a population-based study: The Framingham study. Neurology 1996;46:673-677.
20. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
21. Polvikoski T, Sulkava R, Haltia M, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995;333:1242-1247.
22. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
23. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
24. Suzuki N, Cheung TT, Cai XD, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994;264: 1336-1340.
25. SPSS Inc SPSS for Windows Release 6.1. Chicago, 1994.
26. Evans KC, Berger EP, Cho CG, et al. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA 1995;92:763-767.
27. Palmert MR, Usiak M, Mayeux R, et al. Soluble derivatives of the beta amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and Alzheimer's disease. Neurology 1990;40:1028-1034.
28. Wood SJ Chan W, Wetzel R. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 1996;35:12623-12628.
29. Ma J, Yee A, Brewer HB Jr, et al. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994; 372:92-94.
30. Castano EM, Prelli F, Wisniewski T, et al. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J 1995;306:599-604.
31. Sanan DA, Weisgraber KH, Russell SJ, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils: isoform apoE4 associates more efficiently than apoE3. J Clin Invest 1994;94:860-869.
32. Kamboh MI, Sanghera DK, Ferrell RE, et al. APOE*4-associated Alzheimer's disease risk is modified by alpha1-antichymotrypsin polymorphism. Nat Genet 1995;10:486-488.
33. DeKosky ST, Aston CE, Kamboh MI. Polygenic determinants of Alzheimer's disease: modulation of the risk by alpha-1-antichymotrypsin. Ann NY Acad Sci 1996;802:27-34.
34. Houlden H, Crook R, Duff K, et al. Apolipoprotein E alleles but neither apolipoprotein B nor apolipoprotein AI/CIII alleles are associated with late onset, familial Alzheimer's disease. Neurosci Lett 1995;188:202-204.
35. Marin DB, Breuer B, Marin ML, et al. The relationship between apolipoprotein E, dementia, and vascular illness. Atherosclerosis 1998;140:173-180.